Founder Chairman Erba Group
Can you provide an overview of Erba group and its global business ?
The Erba Group, founded in 1979, is a global company committed to making a social impact worldwide through innovative, affordable, and reliable In Vitro Diagnostics (IVD) solutions. Our global headquarter,
Erba Diagnostics FZ-LLC, is located in Dubai Science Park from where we offer quality services and support globally. The Erba Group spans across the USA, UK, Germany, Czech Republic, France, Austria, Italy, Russia, Ukraine, Turkey, Poland and South East Asia. Through strategic acquisitions, we serve millions in 150 countries. Our production sites in India and the Czech Republic,
along with R&D centers in France, the UK, India, and the Czech Republic, facilitate world-class indigenous research and manufacturing. In fact, our flagship company, Transasia Bio- Medicals Ltd. offers a complete suite of products in the global IVD space, focusing on clinical diagnosis for over 45 years now.
Erba’s growth hinges on a strong commitment to create a “Healthy and Happy world” by offering “Total Diagnostic Solutions” for prevention, early detection and monitoring of diseases. Erba’s “One-stop shop” in the global marketplace, offers everything that a high-tech lab would require such as Clinical Chemistry, Immunology, Haematology, Urine Analysis, Diabetes monitoring,
Autoimmune & Infectious disease monitoring, Molecular Biology, and Microbiology.Our portfolio, crafted through European R&D and low-cost manufacturing, includes instruments and reagent solutions, catering to varied laboratory automation and throughput needs.
With a complete range of diagnostic solutions, and customers in over 150 countries, over 1.5 Billion blood tests were conducted annually
on our analyzers, showcasing our dedication to prevention of disease.
What are your growth plans and business strategy for continuing to be successful in the global diagnostics market?
Operating and providing clinical diagnostic products in over 150 countries, the Erba Group utilizes a combination of cutting-edge European R&D with efficient
low-cost manufacturing to craft innovative technologies that are made accessible to people in all resource settings.
In addressing the global concern of infectious diseases, particularly in emerging countries, the Erba Group is expanding avenues for testing while acknowledging the challenges of quality and affordability in diagnostic solutions. Our commitment extends to catering to these markets with a pipeline of new products, including upcoming releases in molecular testing. To ensure a positive impact beyond regional boundaries, we are actively entering new overseas markets such as Brazil and Russia, providing affordable solutions. With over 12 acquisitions in diverse countries like the Czech Republic, Germany, the U.K., France, Italy, Russia, Turkey, and the U.S., the Erba Group serves millions globally. Even in the on-going geopolitical challenges, we inaugurated a state of-the-art manufacturing facility in Erba Global has been present in most Middle Eastern countries since last 10 years with several hundred installations. It further aims to broaden its reach in UAE, Saudi Arabia, Algeria, Oman and Iraq.
Dubna, Russia, emphasizing our commitment to patient care and making a positive impact during uncertain times. Additionally, we expanded our reach by establishing a subsidiary in Indonesia, reaching out to 300 million people. With a growing momentum and trajectory, our ambitions for 2024 aim to set new heights. Our global R&D efforts, spanning France, the UK, and Austria, are intensifying the focus on developing cutting edge instruments.
How do you differentiate your products and services from competitors?
At Erba, a broad product portfolio, cutting-edge R&D, a global presence and our commitment to excellence sets us apart from competitors in the market. Here are key differentiators that distinguish our products and services: • Initiatives like the ‘NEXUS’ Total Lab Automation solution and novel/patented technologies (Chemiluminescence systems, Molecular testing systems, AI based Hematology systems) distinguish us in the market. NEXUS will provide labs with a modular solution designed to deliver mid-scale, total lab automation across immunology, clinical chemistry and hematology, using a powerful array of technology such as advanced imaging, artificial intelligence, thick film ISE (impregnated Biosensors) and high sensitivity magnetic beads for CLIA analysis. • Utilizing Chemiluminisence technology, the Erba Immunoassay range (IA 40 and Erba Apex IA, Vertex IA & Nexus IA) brings reliability and accessibility to labs looking for efficient and affordable solutions. With a reagent menu of over 100 parameters, these analyzers aid in streamline workflow, optimise space usage and accelerate turn-around time with high reliability upon result quality for laboratories of all size and structure. • MX 8, the Four channel Real Time PCR system is sample-to result 120 min; 8 samples/run
molecular analyzer for decentralised testing. It is a closed extraction and amplification system, together on same unit, that increases specificity by mitigating risks of contamination. MX 8 is affordable, fully automated, is capable of accepting various sample types. Each cartridge has inbuilt internal quality control to verify extraction. MX8 offers far superior performance to smear testing and comes with room temperature stable reagents. Throughput for MX8 (8 samples in 120 mins) is much superior compared to domestic and global players. Currently, we are in the process of validating TB, HIV/HBV/HCV (quant) and triplex HHH, Sickle cell, fever panels. Being affordable, accessible and of superior quality, these solutions will cater to the global markets. • Erba H7100, advanced Hematology Analyzer offers an extensive parameter range, featuring the Retics Panel, Immature Platelet Fraction (IPF), and Immature Granulocytes (IG). These parameters play a pivotal role in the diagnosis, monitoring, and treatment of anemia, thrombocytopenia, thrombocytosis, infection, inflammation, and myeloid neoplasms.
• EC 90, a new electrolyte analyser with maintenance-free electrodes in an all in-one sensor cartridge, aimed at labs of all sizes. The EC 90 directly measures Na+, Cl-, K+ and Ca2+ from whole blood, plasma, serum and pre-diluted urine using a sensor incorporating thick film technology with lower running costs than existing products. • XL200, our signature chemistry analyser, is updated to include a touch screen with improved software for easier operation, longer walk-away time and faster TAT. It will also offer a new ISE module based on the same thick film technology within EC 90. • ELAN 30s – a new fully automated compact benchtop ELISA microstrip processor with easy to use software including QC reports and ability to perform 6 different tests simultaneously. • New Erba LIMS software with mobile app providing high function device interfacing and remote online approval of patient reports, eliminating need for expensive LIS systems. We are very excited to introduce a few of these great new solutions at Medlab this year. By listening to customers and investing in R&D, we are producing a powerful stream of impressive and affordable products. The launch of cutting-edge analyzers is proof of our determination to use best-in-class technology to help labs everywhere access effective automation solutions and reduce running costs.
Further, the Erba Group has always propagated the cause of Science and Healthcare through regular continuing education programs in the field of Laboratory Medicine. The agenda of these programs is to provide a common forum for sharing knowledge, experiences & solutions to help face the challenges in laboratory diagnostics.
Are there specific market segments or regions within the Middle East that you are targeting for growth?
Erba Global has been present in most Middle Eastern countries since last 10 years with several hundred installations. It further aims to broaden its reach in UAE, Saudi Arabia, Algeria, Oman and Iraq.
Can you highlight any recent technological innovations that have positively impacted your business ?
Recent innovations, such as AI- based Hematology systems and advanced Molecular testing systems showcase Erba’s commitment to technological advancements. These breakthroughs address infectious and non-communicable diseases, setting the stage for transformative solutions in 2024.
How do you approach research and development to ensure your products remain cutting-edge?
Erba group has one of the largest network of R&D centers in the world spread across the globe in France, the UK, Czech Republic, and Austria, India, USA with emphasis on cutting-edge technologies. Initiatives like the establishment of a Med-Tech University and ‘Erba Institute of Medical Lab Technology’ demonstrate our dedication to advancing medical technology
Leave feedback about this